A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

Mark Clemons, Michael Ong, Carol Stober, Scott Ernst, Christopher Booth, Christina Canil, Mihaela Mates, Andrew Robinson, Phillip Blanchette, Anil A. Joy, John Hilton, Olexiy Aseyev, Gregory R. Pond, Ahwon Jeong, Brian Hutton, Sasha Mazzarello, Lisa Vandermeer, Igal Kushnir, Dean Fergusson